When evaluated against ovarian cancer, nobiletin reduced VEGF expression by inhibiting AKT activation, thereby reducing angiogenesis and inhibiting tumor proliferation (Chen et al., 2015). The gene discussed is AKT1; the disease is ovarian carcinoma.